Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00434213 · ClinicalTrials.gov registry record · Phase 4
Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
A Phase 4 study, sponsored by Noven Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 309
- Enrollment target
NCT00434213 is a Phase 4 study that has completed, run by Noven Therapeutics. The registered enrollment target is 309 participants.
The verdict
NCT00434213, a Phase 4 study, has completed, sponsored by Noven Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 309 participants
- Enrollment target
Study Summary
This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
Interventions
- DRUG Daytrana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00434213
The ClinicalTrials.gov registry entry for NCT00434213 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 309 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noven Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daytrana is the first listed.
NCT00434213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00434213 about?
NCT00434213 is a clinical study titled "Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA". This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
What is the current status of trial NCT00434213?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 309 participants. The study started on 2007-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00434213?
The interventions under investigation include: Daytrana (DRUG).
Who is sponsoring clinical trial NCT00434213?
This trial is sponsored by Noven Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.